원문 보기
Arc Investment Management CEO Katie Wood is known for her bold predictions . In 2018, when Tesla shares were trading around $300, its bare-bones price forecast led to a 100% increase in shares to $600. What was her prediction for Tesla stock? A whopping $4,000 per share. Over a 1000% increase from the price at the time, taking into account the 5:1 stock split that Tesla implemented in 2020, would mean the stock would be at $800 per share.
This forecast in 2018 seemed optimistic at best. However, considering that Tesla shares are trading at over $600 per share, its forecast is actually quite achievable. Arc Invest's flagship ETF , ARC Innovation, has generated over 100% annualized returns over the past five years, easily making it one of the best-performing ETFs in the world.
A fifth of the return in this ETF is due to the fund holding more than 10% of Tesla shares. Katie recently appeared on the Bloomberg program where she was asked if she thought Tesla would be her best stock over the next 5 years or if another stock would take its place. Her answer was simple: the greatest growth potential over the next five years will be in the genomics field.
For years, if not decades, doctors have been working on DNA sequencing, gene therapy, and now, combined with artificial intelligence, a new form of medicine is on the horizon. For over a hundred years, doctors have been researching the genome or gene editing. However, it was not until 2009 that an editing tool called Crisper was developed, which made genome editing cheaper, easier, and faster.
What does genome editing do? Scientists believe that gene therapy will be able to treat and potentially cure diseases such as cystic fibrosis, diabetes, and even cancer. Essentially, gene therapy involves removing healthy cells from a patient's body and genetically engineering them to attack disease-causing cells.
In 2015, scientists in the UK treated a one-year-old child with leukemia using a genome editing technology called Talons. The treatment was deemed successful, and by all accounts the young patient appears to have recovered. While genome editing has enormous potential, the scientific community is still weighing ethical and safety precautions.
Despite all the risks, investors like Katie Wood are lining up for genomics stocks , and she believes they will be the next Tesla in terms of stock performance growth over the next 5 years. I wonder what stocks Katie has in her genomics portfolio ? Luckily, it's easy to find out, as her company Arc Invest has the Genome Revolution ETF , ticker A R KG.
Top 10 assets in the portfolio: Exact Science Corporation, ticker EXAS, IoVance Biotherapeutics Incorporated, ticker IO VA, CARED X , ticker CDNA, Personalis, ticker PSN, Teldoc Health, ticker TD OC, Invite Corporation, ticker NVTA, Twist Bioscience Corporation, ticker TWWST, Arcturus Therapeutics Holdings Company, ticker ARCT, Pacific Bioscience of California, ticker PACB.
Finally, the largest stock, receiving a 7% weighting in the portfolio, is Crisper Therapeutics, ticker CRSP. Will Katie's predictions about genomics stocks showing the same success as Tesla stock come true? It's hard to argue, given how bold her forecast for Tesla was at the time, but one thing's for sure: Investors are paying a lot more attention to Katie's predictions, given Tesla and her fund's performance over the past few years.
If you want to check out more of Katie's Bloomberg interview, I'll include a link to it in the description below along with links to the Arc Investment ETF where you can learn more about the stocks she holds. Thank you for visiting today. Good luck with your investments.
Comments 0